JP2007504812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504812A5 JP2007504812A5 JP2006525744A JP2006525744A JP2007504812A5 JP 2007504812 A5 JP2007504812 A5 JP 2007504812A5 JP 2006525744 A JP2006525744 A JP 2006525744A JP 2006525744 A JP2006525744 A JP 2006525744A JP 2007504812 A5 JP2007504812 A5 JP 2007504812A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- nos
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102100022641 Coagulation factor IX Human genes 0.000 claims 4
- 108010076282 Factor IX Proteins 0.000 claims 4
- 229960004222 factor ix Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010048049 Factor IXa Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000002947 procoagulating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/661,366 | 2003-09-12 | ||
| US10/661,366 US7297336B2 (en) | 2003-09-12 | 2003-09-12 | Factor IXa specific antibodies displaying factor VIIIa like activity |
| PCT/EP2004/009975 WO2005025615A2 (en) | 2003-09-12 | 2004-09-07 | FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504812A JP2007504812A (ja) | 2007-03-08 |
| JP2007504812A5 true JP2007504812A5 (OSRAM) | 2007-08-16 |
| JP4887148B2 JP4887148B2 (ja) | 2012-02-29 |
Family
ID=34273861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525744A Expired - Fee Related JP4887148B2 (ja) | 2003-09-12 | 2004-09-07 | 第ＶＩＩＩａ因子様活性を示す第ＩＸａ因子特異抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7297336B2 (OSRAM) |
| EP (1) | EP1660536B1 (OSRAM) |
| JP (1) | JP4887148B2 (OSRAM) |
| AT (1) | ATE419277T1 (OSRAM) |
| AU (1) | AU2004271706B2 (OSRAM) |
| CA (1) | CA2538895A1 (OSRAM) |
| DE (1) | DE602004018788D1 (OSRAM) |
| ES (1) | ES2320665T3 (OSRAM) |
| WO (1) | WO2005025615A2 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| EP2824183B1 (en) * | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| EP1760092A1 (en) * | 2005-08-26 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | System for screening cells for high expression of a protein of interest |
| EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR101962483B1 (ko) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| PL2902787T3 (pl) * | 2012-09-28 | 2018-08-31 | Chugai Seiyaku Kabushiki Kaisha | Sposób oceny reakcji krzepnięcia krwi |
| AU2014325063B2 (en) | 2013-09-27 | 2019-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| JP6606505B2 (ja) * | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| BR112018009312A8 (pt) | 2015-12-28 | 2019-02-26 | Chugai Pharmaceutical Co Ltd | método para promover eficiência de purificação de polipeptídeo contendo região de fc |
| SG11201807765PA (en) | 2016-04-28 | 2018-10-30 | Chugai Pharmaceutical Co Ltd | Antibody-containing preparation |
| EP3458477B1 (en) * | 2016-05-16 | 2025-07-09 | Takeda Pharmaceutical Company Limited | Anti-factor ix padua antibodies |
| EP3509637B1 (en) | 2016-09-06 | 2024-11-27 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| CA3034105A1 (en) * | 2016-09-23 | 2018-03-29 | Csl Limited | Coagulation factor binding proteins and uses thereof |
| MX2019005772A (es) * | 2016-11-23 | 2019-10-02 | Bioverativ Therapeutics Inc | Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x. |
| CA3051639A1 (en) | 2017-02-01 | 2018-08-09 | Novo Nordisk A/S | Procoagulant antibodies |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CA3071236A1 (en) | 2017-09-29 | 2019-04-04 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient |
| CR20240273A (es) | 2017-11-01 | 2024-08-27 | Chugai Pharmaceutical Co Ltd | Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229) |
| MY202203A (en) | 2018-08-01 | 2024-04-17 | Novo Nordisk As | Improved procoagulant antibodies |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| WO2020128049A1 (en) * | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
| US20250376538A1 (en) | 2020-01-30 | 2025-12-11 | Novo Nordisk A/S | Bispecific factor viii mimetic antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT368883B (de) | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0658168B1 (en) | 1992-08-27 | 2000-11-15 | Stichting Sanquin Bloedvoorziening | Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein |
| DK128093D0 (da) | 1993-11-12 | 1993-11-12 | Novo Nordisk As | Hidtil ukendte forbindelser |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| WO1999001476A1 (en) | 1997-07-03 | 1999-01-14 | Smithkline Beecham Corporation | CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| CN100503639C (zh) * | 2001-05-03 | 2009-06-24 | 默克专利有限公司 | 重组肿瘤特异性抗体及其应用 |
-
2003
- 2003-09-12 US US10/661,366 patent/US7297336B2/en not_active Expired - Lifetime
-
2004
- 2004-09-07 JP JP2006525744A patent/JP4887148B2/ja not_active Expired - Fee Related
- 2004-09-07 ES ES04764918T patent/ES2320665T3/es not_active Expired - Lifetime
- 2004-09-07 AT AT04764918T patent/ATE419277T1/de active
- 2004-09-07 CA CA002538895A patent/CA2538895A1/en not_active Abandoned
- 2004-09-07 AU AU2004271706A patent/AU2004271706B2/en not_active Expired
- 2004-09-07 EP EP04764918A patent/EP1660536B1/en not_active Expired - Lifetime
- 2004-09-07 DE DE602004018788T patent/DE602004018788D1/de not_active Expired - Lifetime
- 2004-09-07 WO PCT/EP2004/009975 patent/WO2005025615A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504812A5 (OSRAM) | ||
| EP3910065B1 (en) | Interleukin -13 binding proteins | |
| US20220289858A1 (en) | Anti-cd40 antibodies and uses thereof | |
| CN102421795B (zh) | 针对肌钙蛋白i的抗体及其使用方法 | |
| CN114539414B (zh) | 抗凝血因子xi抗体 | |
| JP5964249B2 (ja) | 治療用ｄｌｌ４結合タンパク質 | |
| AU2009279804C1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (TFPI) | |
| JP2011527902A5 (OSRAM) | ||
| JP2008542278A5 (OSRAM) | ||
| US20130267688A1 (en) | Novel antibody structures derived from human germline sequences | |
| CN102076714A (zh) | 结合Aβ(1-42)球聚体的人源化抗体及其应用 | |
| JP7028471B2 (ja) | 第ｘｉ因子の活性部位に対するモノクローナル抗体及びその使用 | |
| CN105102480A (zh) | 催乳素受体结合蛋白及其用途 | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| Roque-Navarro et al. | Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method | |
| JP2021101720A (ja) | 抗凝固因子ｘｉ抗体 | |
| JP2024105229A5 (OSRAM) | ||
| JP2010527939A5 (OSRAM) | ||
| JP2010501164A5 (OSRAM) | ||
| IL265350B2 (en) | Antibody specifically binding to il-17a and functional fragment thereof | |
| JP2009509538A5 (OSRAM) | ||
| CN111492066A (zh) | 使用转录本进行抗体方向的方法及由其衍生的组合物 | |
| JP2005510201A5 (OSRAM) | ||
| CN110423278B (zh) | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 | |
| CN114656556A (zh) | 一种抗新型冠状病毒的全人源单克隆抗体及其应用 |